Prospective evaluation of NGS-based liquid biopsy in untreated late stage non-squamous lung carcinoma in a single institution

scientific article published on 17 February 2020

Prospective evaluation of NGS-based liquid biopsy in untreated late stage non-squamous lung carcinoma in a single institution is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1186/S12967-020-02259-2
P932PMC publication ID7027049
P698PubMed publication ID32066459

P50authorSimon HeekeQ61118563
P2093author name stringPaul Hofman
Véronique Hofman
Charles-Hugo Marquette
Maryline Allegra
Marius Ilié
Virginie Tanga
Christelle Bonnetaud
Michel Poudenx
Olivier Bordone
Jonathan Benzaquen
Jacques Boutros
Salomé Lalvée
Virginie Lespinet
Carole Salacroup
P2860cites workAn ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.Q33590850
Functional consequence of the MET-T1010I polymorphism in breast cancerQ35550045
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung CancerQ38975751
Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer.Q48507434
Optimization of EGFR mutation detection by the fully-automated qPCR-based Idylla system on tumor tissue from patients with non-small cell lung cancer.Q49417517
Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling.Q50128100
Use of the Ion PGM and the GeneReader NGS Systems in Daily Routine Practice for Advanced Lung Adenocarcinoma Patients: A Practical Point of View Reporting a Comparative Study and Assessment of 90 Patients.Q51760971
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upQ57051777
Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung CancerQ57476349
TAC-seq: targeted DNA and RNA sequencing for precise biomarker molecule countingQ60301211
Critical Assessment in Routine Clinical Practice of Liquid Biopsy for EGFR Status Testing in Non-Small-Cell Lung Cancer: A Single-Laboratory Experience (LPCE, Nice, France)Q90099242
Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET studyQ90215699
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumabQ90788586
Liquid biopsy and minimal residual disease - latest advances and implications for cureQ91845060
Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome ConsortiumQ92493647
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapyQ92578527
Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung CancerQ93109964
A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung CancersQ93367319
P433issue1
P921main subjectlung carcinomaQ18556110
P304page(s)87
P577publication date2020-02-17
P1433published inJournal of Translational MedicineQ15716664
P1476titleProspective evaluation of NGS-based liquid biopsy in untreated late stage non-squamous lung carcinoma in a single institution
P478volume18

Reverse relations

Q98948993Predictive molecular pathology in non-small cell lung cancer in France: The past, the present and the perspectivescites workP2860

Search more.